• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Christene A. Huang, PhD

Associate Professor, Department of Surgery, Harvard Medical School

Scientific Co-Director, Recombinant Protein Expression and Purification Core Facility, Dana-Farber/Harvard Cancer Center

Associate Immunologist, Surgery, Massachusetts General Hospital

Contact Info

Christene Huang
Massachusetts General Hospital
149 13th Street

Charlestown, MA, 02129
Mailstop: 9019
Phone: 617-726-6505
Fax: 617-726-4067


Lisa Bernardo
Administrative Staff Assistant III
Transplantation Biology Research Center
Massachusetts General Hospital
13th Street
Boston, MA, 02129
Phone: 617-726-4066
Fax: 617-726-4067

DF/HCC Program Affiliation

Lymphoma and Myeloma

Research Abstract

Hematopoietic cell transplantation (HCT) can be an effective approach to induce allograft tolerance, replace defective blood lineages and cure hematological malignancies. Unfortunately, the toxicities associated with HCT protocols that reliably establish stable engraftment limit this approach in the clinic. Toxicities include complications resulting from cytotoxic conditioning and graft versus host disease (GvHD). One of my major scientific achievements has been the development of a novel, minimally toxic protocol that reliably establishes hematopoietic stem cell engraftment and tolerance across haploidentical MHC barriers in miniature swine without GvHD. As a confirmation of the clinical relevance of the miniature swine model, haploidentical HCT following standard myeloablation uniformly results in severe GvHD and/or hematopoietic failure. Preliminary data from my research suggest that mild HCT protocols that preserve regulatory T-cell development and function may be more successful in achieving stable donor stem cell engraftment while avoiding GvHD than those that rely on harsh conditioning and complete donor and host T-cell depletion. Another major scientific achievement has been the establishment of several leukemia and lymphoma cell lines derived from the bone marrow of older miniature swine that spontaneously developed chronic myelogenous leukemia over the past ten years as well as from experimental animals that developed post-transplantation lymphoproliferative disorder. Recently one of the myeloid leukemia cell lines demonstrated growth in vivo when injected intraosseously into MHC-matched miniature swine. The goal of these tumor studies is to develop transplantable tumor models in miniature swine to enable direct assessment of tumor immunotherapy in a clinically relevant large animal model.


View All Publications